FDA Extends Review of Capricor's Duchenne Therapy

Capricor Therapeutics said 24 August 2026 that FDA has pushed the target action date on its deramiocel Biologics License Application from 22 August to 22 November — a three-month extension triggered by a major amendment built on two more years of trial follow-up and a proposed indication narrowed to the one endpoint that held up best in the data.

A narrower claim after a lost vote

Deramiocel's review has moved in a straight line of escalating specificity. FDA's first Complete Response Letter, in July 2025, found the BLA had not established substantial evidence of effectiveness for the broad indication Capricor had proposed. FDA lifted that CRL in March 2026 and resumed review as a Class 2 resubmission, setting 22 August as the target action date. In July, an FDA advisory committee — convened to weigh the resubmitted evidence for treating Duchenne muscular dystrophy-associated cardiomyopathy — voted 9-3 against recommending approval, with members who voted no generally pointing to instability in the statistical results depending on how missing data were handled. Rather than wait for a straight up-or-down decision on the indication the committee had just rejected, Capricor amended the application: it added two more years of open-label HOPE-3 follow-up and asked FDA to consider a narrower claim, anchored specifically to upper-limb function rather than the broader cardiomyopathy claim.

Why upper-limb function

HOPE-3's primary endpoint was always upper-limb function, measured on the Performance of Upper Limb 2.0 scale, and it is the result that held up best statistically: a 54% slowing of decline versus placebo, at P=.029. The trial's key secondary endpoint, a 91% slowing of decline in left ventricular ejection fraction versus placebo (P=.041), speaks more directly to cardiomyopathy — the indication the advisory committee rejected — but the committee's stated concerns centered on the robustness of that secondary analysis, not the primary one. Narrowing the proposed label to the primary endpoint is a bet that a claim built on the trial's strongest, least-contested result stands a better chance than the broader claim that just lost a committee vote, even though it would mean a more limited approved use if deramiocel is cleared.

What the extension does and does not mean

FDA classifying a submission as a major amendment is a procedural, not a substantive, signal: under standard PDUFA review-clock rules, a major amendment filed close to the original target date routinely adds up to three months, regardless of the amendment's ultimate merits. It does not indicate FDA's view on whether the refined indication clears the bar the July committee found lacking for the broader one. Capricor now has until 22 November for a decision that, given deramiocel's history, has already produced one CRL and one adverse advisory vote before reaching this point. Duchenne muscular dystrophy remains a disease with no cell-therapy option approved in the U.S. and only a small number of approved treatments overall, which is the unmet-need backdrop against which FDA's cell and gene therapy reviewers are weighing the narrower claim.